FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.
What happened
FDA inspected the company’s finished-drug manufacturing facility from January 16 to 24, 2025. Investigators found residues of multiple active ingredients on non-dedicated equipment that records said had been cleaned, non-sterile tape and loose fittings in an ISO 5 aseptic area, and inadequate validation of tablet compression reject limits. They also observed a laboratory employee who appeared to approve environmental monitoring records non-contemporaneously.
What FDA found
The company did not adequately clean non-dedicated manufacturing equipment; residues containing multiple active ingredients were found on surfaces recorded as cleaned.
21 CFR 211.67(a)In an ISO 5 aseptic area, the company used non-sterile tape and had equipment that was not securely fastened, without informing the quality unit.
21 CFR 211.42(c)(10)The company lacked adequate written production and process controls and validation data for tablet compression reject limits.
21 CFR 211.100(a)A laboratory employee appeared to approve environmental monitoring records non-contemporaneously, raising concerns about data reliability.
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, including comprehensive cleaning and contamination risk assessments, CAPA plans, and validation plans. FDA also recommends engaging a qualified CGMP consultant to audit the operation.
Who should pay attention
- brands and distributors sourcing finished drugs from this site
- patients taking prescription drugs made there
- sterile drug manufacturers and contractors using aseptic processing
This is a summary. Read the original letter on fda.gov.